HighTower Advisors LLC Takes $38,000 Position in Fractyl Health, Inc. (NASDAQ:GUTS)

HighTower Advisors LLC bought a new stake in Fractyl Health, Inc. (NASDAQ:GUTS) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 15,000 shares of the company’s stock, valued at approximately $38,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Rhumbline Advisers acquired a new position in Fractyl Health in the 2nd quarter valued at $32,000. SG Americas Securities LLC acquired a new position in Fractyl Health in the 3rd quarter worth about $33,000. Renaissance Technologies LLC bought a new position in Fractyl Health in the second quarter valued at about $61,000. Beta Wealth Group Inc. acquired a new stake in Fractyl Health during the 3rd quarter worth approximately $44,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Fractyl Health by 54.1% during the third quarter. BNP Paribas Financial Markets now owns 21,072 shares of the company’s stock valued at $53,000 after acquiring an additional 7,397 shares during the last quarter.

Insider Transactions at Fractyl Health

In related news, CEO Harith Rajagopalan sold 96,517 shares of the business’s stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $2.47, for a total value of $238,396.99. Following the sale, the chief executive officer now directly owns 491,329 shares in the company, valued at approximately $1,213,582.63. The trade was a 16.42 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Jay David Caplan sold 64,197 shares of Fractyl Health stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $2.47, for a total transaction of $158,566.59. Following the completion of the transaction, the insider now owns 153,544 shares of the company’s stock, valued at $379,253.68. This represents a 29.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Fractyl Health Stock Up 7.3 %

Fractyl Health stock opened at $2.06 on Friday. Fractyl Health, Inc. has a 52-week low of $1.74 and a 52-week high of $14.50. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. The firm has a 50 day moving average price of $2.34 and a two-hundred day moving average price of $3.08. The firm has a market cap of $99.08 million and a price-to-earnings ratio of -0.17.

Fractyl Health (NASDAQ:GUTS) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.50) by $0.02. The company had revenue of $0.01 million for the quarter. Equities analysts predict that Fractyl Health, Inc. will post -1.66 EPS for the current year.

Fractyl Health Profile

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.